Retatrutide Delivers Unprecedented Weight Loss in Phase 3
Eli Lilly's retatrutide has shown significant weight loss results in the TRIUMPH-1 phase 3 trial. Participants lost an average of 28.3% of their body weight over 80 weeks, with some achieving a BMI below 30. Experts express cautious optimism, noting the need for further peer-reviewed data to confirm these findings.
- ▪Retatrutide is a triple hormone receptor agonist that activates GIP, GLP-1, and glucagon receptors.
- ▪Participants on the 12 mg dose lost an average of 28.3% of their body weight, while 45.3% achieved ≥ 30% weight loss.
- ▪Two-thirds of participants on the highest dose achieved a BMI less than 30, indicating a move out of the obesity range.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/retatrutide-delivers-unprecedented-weight-loss-phase-3-2026a1000gl4?src=rss |
| Publication time | Thu, 21 May 2026 15:18:02 EDT |
| Retrieval time | 2026-05-21T19:31:35.709Z |
| Last seen | 2026-05-21T19:31:35.709Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | 6y1aBYZwUT0B |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Retatrutide, Eli Lilly’s first-in-class triple hormone receptor agonist, delivered meaningful weight loss at 80 weeks in all doses in the TRIUMPH-1 phase 3 trial.Retatrutide is an investigational, triple hormone receptor agonist that activates the body's receptors for GIP, GLP-1, and glucagon. It’s given as a once-weekly injection.Meaningful Results at Three Doses Trial participants were adults with obesity or overweight and at least one weight-related health condition, but without diabetes. They were randomized to one of three retatrutide doses or placebo for 80 weeks.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
